Open Monoclonal Technology Inc:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Open Monoclonal Technology Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C11475)・商品コード:DATA904C11475
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:34
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Open Monoclonal Technology Inc (OMT), a subsidiary of Ligand Pharmaceuticals Inc, is a biotechnology company that discovers and develops human monoclonal antibody platform based on transgenic rats. The company provides products such as omnirat, omnimouse and omniflic. Its omnirat is an antibody platform that generates human monoclonal antibodies based on transgenic rats. OMT’s omnimouse is a transgenic mouse that complements omnirat and expands epitope coverage. The company’s omniflic is the rat engineered with a fixed light chain for discovery of bi-specific, fully human antibodies. It serves pharmaceutical and biotech companies. The company offers alternative to generating and characterizing human antibody development candidates. OMT is headquartered in San Diego, California, the US.

Open Monoclonal Technology Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Symphogen Enters Into Agreement With Open Monoclonal Technology 11
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 12
Open Monoclonal Expands Agreement with CNA Development 13
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 14
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 15
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 16
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 17
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 18
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 19
Licensing Agreements 20
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 21
Open Monoclonal Enters into Licensing Agreement with Celgene 22
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 23
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 24
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 25
Open Monoclonal Enters into Licensing Agreement with Amgen 26
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 27
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 28
Acquisition 29
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 29
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology’s Spin-Out Companies 30
Open Monoclonal Technology Inc – Key Competitors 31
Open Monoclonal Technology Inc – Key Employees 32
Open Monoclonal Technology Inc – Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Key Facts 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Symphogen Enters Into Agreement With Open Monoclonal Technology 11
Open Monoclonal Technology Enters Into Agreement With CNA Development For OmniRat Antibody 12
Open Monoclonal Expands Agreement with CNA Development 13
Crystal Biosciences Enters Into Agreement With Open Monoclonal Technology For Gel-Encapsulated Microenvironment Technology 14
Single Cell Technology Enters Into Co-Development Agreement With Open Monoclonal Technology 15
Trellis Bioscience Enters Into Agreement With Open Monoclonal Technology To Discover Human Therapeutic Antibodies 16
WuXi PharmaTech Expands Agreement with Open Monoclonal Technology 17
Open Monoclonal Technology Enters Into Antibody Discovery Agreement With Merck 18
EMD Serono And Open Monoclonal Technology Expand Discovery Agreement For OmniRat 19
ARMO BioSciences Enters into Licensing Agreement with Open Monoclonal 20
Open Monoclonal Enters into Licensing Agreement with University of Nottingham 21
Open Monoclonal Enters into Licensing Agreement with Celgene 22
Pfizer Enters into Licensing Agreement with Open Monoclonal Technology 23
Seattle Genetics Enters into Licensing Agreement with Open Monoclonal Technology 24
Five Prime Therapeutics Enters into Licensing Agreement with Open Monoclonal 25
Open Monoclonal Enters into Licensing Agreement with Amgen 26
HanAll BioPharma Enters into Licensing Agreement with Open Monoclonal 27
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 28
Ligand Pharma Acquires Open Monoclonal Technology for USD178 Million 29
Genentech And F. Hoffmann-La Roche To Acquire Open Monoclonal Technology's Spin-Out Companies 30
Open Monoclonal Technology Inc, Key Competitors 31
Open Monoclonal Technology Inc, Key Employees 32

List of Figures
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Open Monoclonal Technology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Open Monoclonal Technology Inc:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C11475)販売に関する免責事項を必ずご確認ください。
★調査レポート[Open Monoclonal Technology Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆